Resources
About Us
Home Report
Store
Point of care Diagnostics Market
Point of care Diagnostics Market by Application (Influenza, Pneumonia, HAI, Salmonellosis, Hepatitis, HIV, COVID, Pregnancy, Glucose Monitoring, Hematology, Tumor Marker, Urinalysis), Platform (LFA, Molecular), Sample, End User - Global Forecast to 2030
Report ID:MRHC - 10499 Pages: 395 May-2023 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursPoint of care Diagnostics Market Size & Forecast
Point of care Diagnostics Market is expected to reach $43.1 billion by 2030, at a CAGR of 5.1% from 2023–2030. The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC testing, development of CLIA-waived PoC testing, and lack of Skilled technicians for performing lab tests. In addition, emerging markets and healthcare professionals’ increasing preference for PoC tests over lab tests are expected to offer significant market growth opportunities. However, pricing pressure due to fluctuations in reimbursements restrains the growth of this market.
Technological Trends in the Point-of-care Diagnostics Market
Technological trends such as lateral flow assays containing DNA nanostructures, rapid real-time polymerization chain reaction (PCR) tests, smartphone-based detection platforms, and nanoelectronic biosensors in point-of-care diagnostics lead to growth in demand for PoC diagnostics products.
Traditional antibodies in lateral flow assays can be replaced with DNA nanostructures capable of binding with a target antigen with high binding affinity and specificity. For example, Atom Bioworks Inc. (U.S.) has developed the DNA Star PoC Diagnostics Platform, a lateral flow assay kit that contains nanoengineered DNA nanostructures instead of traditional antibodies. In 2021, the company was awarded the Rapid Testing Innovation Award at the Advanced Lateral Flow Conference organized by DCN Diagnostics (U.S.) and DIALUNOX GmbH (Germany).
Smartphone-based platforms find applications in tele-imaging, food technology, and education. Smartphone-based detection is versatile and has a wide range of medical applications. Point-of-care diagnostics play a key role in screening patients at any healthcare unit. With high diagnosis costs and the limited availability of benchtop readers in remote/resourceless areas, the demand for smartphone-based point-of-care diagnostics is rising continuously.
Click here to: Get a Free Sample Copy of this report
Emerging Markets Create an Opportunity for the Market Growth
Emerging economies are fueling the demand for healthcare services and treatments due to rapid urbanization, improving healthcare infrastructures, increasing healthcare expenditures, growing healthcare insurance coverage, rising disposable incomes, and the growing prevalence of non-communicable and infectious diseases.
According to World Bank data, the total population in emerging countries is projected to reach 3.4 billion by 2050. Similarly, diabetes cases in emerging countries are rising. According to the IDF Diabetes Atlas 2021, diabetes cases in South Africa, India, Malaysia, Brazil, China, and Thailand increased from 171.6 million in 2011 to 245.5 million in 2021, indicating the high potential for the adoption of point-of-care diagnostic kits for blood glucose screening.
Moreover, growing urbanization and rising GDP per capita drive the demand for healthcare services and treatments in emerging economies such as South Africa, India, Brazil, China, Bangladesh, and Thailand. Growing urbanization indicates higher wages, a better quality of life, and improved access to healthcare services. Therefore, growing urbanization in emerging economies is expected to drive the development of healthcare systems, increasing people’s access to healthcare services and leading to the proliferation of hospitals, clinics, and diagnostic laboratories in these countries.
Key Findings of the Point-of-care Diagnostics Market Study:
Based on Offering, the Consumables Segment is Estimated to Dominate the Point-of-care Diagnostics Market in 2023
Based on offering, the global point-of-care diagnostics market is segmented into consumables, instruments, and software and services. In 2023, the consumables segment is expected to account for the largest share of the global point-of-care diagnostics market. The large market share of this segment is attributed to the benefits offered by point-of-care diagnostics kits, such as ease of use, portability, and accuracy.
PoC diagnostic kits are pre-packaged sets of materials and reagents used for performing tests. These diagnostic kits are user-friendly, with clear instructions for use and require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, such as rural or remote areas.
The Molecular Diagnostics Platform Segment is Expected to Register the Highest CAGR During the Forecast Period
Based on platform, the global point-of-care diagnostics market is segmented into lateral flow assays (LFA), molecular diagnostics, and other platforms. The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is driven by the high sensitivity and accuracy of these tests, the growing need for advanced diagnostic techniques, and the widening applications of molecular detection tests in various fields.
Based on Application, in 2023, the Blood Glucose Monitoring Segment is Estimated to Account for the Largest Share of the Market
Based on application, the global point-of-care diagnostics market is segmented into infectious disease testing, blood glucose monitoring, cardiac marker/cardiac metabolism testing, COVID-19 testing, coagulation testing, pregnancy and fertility testing, fecal occult testing, hematology, tumor/cancer markers testing, drugs of abuse testing, urinalysis, cholesterol/lipid profile testing, other POC testing.
In 2023, the blood glucose monitoring segment is expected to account for the largest share of the global POC diagnostics market. The increased prevalence of diabetes and the need for glucose monitoring devices increased the demand for blood glucose monitoring PoC diagnostics devices.
The Blood Sample Type Segment is Expected to Register the Highest CAGR During the Forecast Period
Based on sample type, the global point-of-care diagnostics market is segmented into blood sample, urine sample, saliva sample, nasopharyngeal swab, and other sample types. The blood sample type segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is driven by the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.
The Home Care/Self-Testing Segment is Expected to Register the Highest CAGR during the Forecast Period
Based on end user, the global point-of-care diagnostics market is segmented into home care/self-testing, hospitals, physician offices & ambulatory care settings, diagnostics laboratories, and other end users. The fast growth of the home care/self-testing segment is primarily attributed to the increasing prevalence of chronic diseases requiring long-term care and frequent monitoring, increasing home healthcare spending, growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products. For instance, in the U.S., home healthcare spending increased from USD 88,800 million in 2015 to USD 1,17,100 million in 2020.
Asia-Pacific: Fastest Growing Regional Market
Asia-Pacific is expected to register the highest CAGR during the forecast period. Asia-Pacific is becoming an attractive market for healthcare product manufacturers due to the continuous improvement in the healthcare infrastructure, the rising number of hospitals, and growing government investment in this sector. Accelerated economic growth in many countries of the Asia-Pacific region has relatively increased the focus of various governments on the healthcare sector in terms of increased investments to enhance the accessibility to healthcare facilities and build better healthcare infrastructure.
Point of care Diagnostics Companies
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).
Scope of Point of care Diagnostics Market Report:
Point-of-care Diagnostics Market Assessment, by Offering
- Consumables
- Instruments
- Software and Services
Point-of-care Diagnostics Market Assessment, by Platform
- Lateral Flow Assays
- Molecular Diagnostics
- Other Platforms
(Note: Other platforms majorly include coagulation tests, dipsticks, cholesterol and glucose monitoring systems, and other point-of-care diagnostic platforms)
Point-of-care Diagnostics Market Assessment, by Application
- Blood Glucose Monitoring
- Infectious Disease Testing
- Parasitic Infection Testing
- Blood-borne Infection Testing
- Hepatitis
- HIV
- Other Blood-borne Infections
- Respiratory Infections Testing
- Influenza
- Pneumonia
- Other Respiratory Infections Testing
- Healthcare-associated Infection (HAI) Testing
- Gastrointestinal (GI) Infection Testing
- Salmonellosis
- E. Coli Infections
- Other GI Infections
- Other Infectious Disease Testing
- COVID-19 Testing
- Tumor/Cancer Markers Testing
- Pregnancy And Fertility Testing
- Pregnancy Testing
- Fertility Testing
- Cardiac Marker/Cardiac Metabolism Testing
- Cholesterol/Lipid Profile Testing
- Coagulation Testing
- Prothrombin Time (PT/INR) Testing
- Activated Clotting Time (ACT/APTT) Testing
- Other Coagulation Testing
- Hematology
- Drugs Of Abuse Testing
- Urinalysis
- Other PoC Testing
(Other respiratory infections testing include strep infections and respiratory syncytial virus (RSV). Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis. Other blood-borne diseases include syphilis and brucellosis. Other infectious disease testing includes meningitis, hand, foot, and mouth disease (HFMD), and mononucleosis. Other coagulation testing segment includes fibrinogen level and platelet count. Other PoC testing includes tropical diseases and sexually transmitted diseases)
Point-of-care Diagnostics Market Assessment, by Sample Type
- Blood Sample
- Nasopharyngeal Swab
- Urine Sample
- Saliva Sample
- Other Sample Types
(Other sample types include stool, cervical swab, buccal swab, hair, vaginal swab, and semen)
Point-of-care Diagnostics Market Assessment, by End User
- Hospitals
- Home care/self-testing
- Physician Offices & Ambulatory Care Settings
- Diagnostics Laboratories
- Other End Users
(Other end users include nursing homes, long-term care centers, pharmacies, urgent care facilities, schools, airports, hotels, and workplaces)
Point-of-care Diagnostics Market Assessment, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
Key questions answered in the report:
The point-of-care diagnostics market study covers the market sizes & forecasts for various point-of-care diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the point-of-care diagnostics market at the regional and country levels.
The global point-of-care diagnostics market is projected to reach $43.1 billion by 2030, at a CAGR of 5.1% during the forecast period.
Which PoC diagnostic application segment is estimated to hold the major share of the market in 2023?
The blood glucose monitoring segment is estimated to account for the largest share of the point-of-care diagnostics market in 2023. Factors such as the rising prevalence of diabetes, advancements in diagnostics products, and increasing awareness among the population for regular health checkups contribute to the largest segment share.
Based on the platform, in 2023, the LAF segment is estimated to hold the major share, owing to factors such as their one-step process, long shelf life, higher portability & lower costs compared to laboratory-based tests
Based on sample type, the blood sample segment is projected to create more traction during the forecast period due to the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.
Based on end user, in 2023, the hospitals segment is estimated to hold the major share due to an increasing patient inflow, well-established infrastructure, and technological advancements.
The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, the development of CLIA-waived PoC tests, and the lack of skilled technicians for performing lab tests. In addition, emerging markets and healthcare professionals’ increasing preference for PoC tests over lab tests are expected to offer significant market growth opportunities.
The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).
The emerging Asian-Pacific countries are projected to offer significant growth opportunities for the vendors in this market due to the continuous improvement in the healthcare infrastructure, the rising number of hospitals, and growing government investment in this sector.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Chronic Diseases
4.2.2. Innovations in PoC Tests
4.2.3. Development of CLIA-waived PoC Tests
4.2.4. Lack of Skilled Technicians for Performing Lab Tests
4.3. Restraints
4.3.1. Pricing Pressure Due to Fluctuations in Reimbursements
4.4. Opportunities
4.4.1. Emerging Markets
4.4.2. Healthcare Professionals’ Increasing Preference for PoC Tests Over Other Lab Tests
4.5. Challenges
4.5.1. Lack of Awareness Regarding the Use of PoC Devices
4.6. Technology Trends
4.6.1. Lateral Flow Assays Containing DNA Nanostructures
4.6.2. Rapid Real-time Polymerization Chain Reaction (PCR) Tests
4.6.3. Smartphone-based Detection Platforms
4.6.4. Nanoelectronic Biosensors in Point-of-Care Diagnostics
4.7. Regulatory Analysis
4.7.1. U.S.
4.7.2. Canada
4.7.3. Europe
4.7.4. China
4.7.5. Japan
4.7.6. Latin America
4.7.7. Saudi Arabia
4.8. Pricing Analysis
5. Point-of-Care Diagnostics Market Assessment—by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software And Services
6. Point-of-Care Diagnostics Market Assessment—by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.3. Molecular Diagnostics
6.4. Other Platforms
7. Point-of-Care Diagnostics Market Assessment—by Application
7.1. Overview
7.2. Blood Glucose Monitoring
7.3. Infectious Disease Testing
7.3.1. Parasitic Infections Testing
7.3.2. Blood-borne Infections Testing
7.3.2.1. Hepatitis
7.3.2.2. HIV
7.3.2.3. Other Blood-borne Infections
7.3.3. Respiratory Infections Testing
7.3.3.1. Influenza
7.3.3.2. Pneumonia
7.3.3.3. Tuberculosis (TB)
7.3.3.4. Other Respiratory Infections Testing
7.3.4. Healthcare-associated Infections (HAI) Testing
7.3.5. Gastrointestinal Infections Testing
7.3.5.1. Salmonellosis
7.3.5.2. E. Coli Infections
7.3.5.3. Other GI Infections
7.3.6. Other Infectious Diseases Testing
7.4. COVID-19 Testing
7.5. Tumor/Cancer Markers Testing
7.6. Pregnancy And Fertility Testing
7.6.1. Pregnancy Testing
7.6.2. Fertility Testing
7.7. Cardiac Marker/Cardiac Metabolism Testing
7.8. Cholesterol/Lipid Profile Testing
7.9. Coagulation Testing
7.9.1. Prothrombin Time (PT/INR) Testing
7.9.2. Activated Clotting Time (ACT/APTT) Testing
7.9.3. Other Coagulation Testing
7.10. Hematology
7.11. Drugs of Abuse Testing
7.12. Urinalysis
7.13. Other PoC Testing
8. Point-of-Care Diagnostics Market Assessment—by Sample Type
8.1. Overview
8.2. Blood Sample
8.3. Nasopharyngeal Swab
8.4. Urine Sample
8.5. Saliva Sample
8.6. Other Sample Types
9. Point-of-Care Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals
9.3. Home Care/Self-testing
9.4. Physician Offices & Ambulatory Care Settings
9.5. Diagnostics Laboratories
9.6. Other End Users
10. Point-of-Care Diagnostics Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Dashboard
11.3.1. Industry Leaders
11.3.2. Market Differentiators
11.3.3. Vanguards
11.3.4. Emerging Companies
11.4. Market Share Analysis (2022)
11.4.1. Abbott Laboratories
11.4.2. F. Hoffmann-La Roche Ltd
11.4.3. Siemens Healthineers AG
11.4.4. Danaher Corporation
11.4.5. Thermo Fisher Scientific, Inc.
12. Company Profiles
12.1. Abbott Laboratories
12.2. F. Hoffmann-La Roche Ltd
12.3. Siemens Healthineers AG
12.4. Danaher Corporation
12.5. Thermo Fisher Scientific Inc.
12.6. Becton, Dickinson and Company (BD)
12.7. bioMérieux S.A.
12.8. QuidelOrtho Corporation
12.9. EKF Diagnostics Holdings plc
12.10. Sekisui Diagnostics, LLC.
12.11. Trinity Biotech plc
12.12. Chembio Diagnostics, Inc.
12.13. Werfen
12.14. Nova Biomedical
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Global Diabetes Prevalence in People Aged 20–79 Years, by Region, 2021 VS. 2030 VS. 2045 (Million)
Table 2 PoC Products with CLIA Waiver
Table 3 Percentage of Population Residing in Urban Areas, 2015 VS. 2025 VS. 2050 (Emerging Countries)
Table 4 Authorities Regulating In Vitro Diagnostic Products, by Country
Table 5 Price Comparison of Point-of-Care Tests
Table 6 Price Comparison of Glucose Monitoring Tests
Table 7 Global Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 8 Key Companies Offering Consumables
Table 9 Global Point-of-Care Diagnostics Consumables Market, by Country/Region, 2021–2030 (USD Million)
Table 10 Key Companies Offering Instruments
Table 11 Global Point-of-Care Diagnostics Instruments Market, by Country/Region, 2021–2030 (USD Million)
Table 12 Key Companies Offering Software and Services
Table 13 Global Point-of-Care Diagnostics Market for Software and Services, by Country/Region, 2021–2030 (USD Million)
Table 14 Global Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 15 Key Companies Offering Lateral Flow Assays
Table 16 Global Point-of-Care Diagnostics Market for Lateral Flow Assays, by Country/Region, 2021–2030 (USD Million)
Table 17 Key Companies Offering Rapid PCR Test Kits
Table 18 Global Point-of-Care Diagnostics Market for Molecular Diagnostics, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Point-of-Care Diagnostics Market for Other Platforms, by Country/Region, 2021–2030 (USD Million)
Table 20 Global Point-of-Care Diagnostics Market, by Application, 2021–2030
Table 21 Number of People with Diabetes Aged 20–79 Years, by Region
Table 22 Global Point-of-Care Diagnostics Market for Blood Glucose Monitoring, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Type, 2021–2030 (USD Million)
Table 24 Global Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Country/Region, 2021–2030 (USD Million)
Table 25 Global Point-of-Care Diagnostics Market for Parasitic Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 26 Global Point-of-Care Diagnostics Market for Blood-borne Infections Testing, by Type, 2021–2030 (USD Million)
Table 27 Global Point-of-Care Diagnostics Market for Blood-borne Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 28 Current and Future Reduction Targets for Hepatitis Infection
Table 29 Global Point-of-Care Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 30 HIV Incidence 2020 Vs. 2021
Table 31 HIV-related Deaths, 2020 Vs. 2021
Table 32 Global Point-of-Care Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 33 Global Point-of-Care Diagnostics Market for Other Blood-borne Infections, by Country/Region, 2021–2030 (USD Million)
Table 34 Global Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 35 Rapid Influenza Diagnostic Tests (RIDTs)
Table 36 Global Point-of-Care Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 37 Global Point-of-Care Diagnostics Market for Pneumonia, by Country/Region, 2021–2030 (USD Million)
Table 38 Global Point-of-Care Diagnostics Market for Tuberculosis, by Country/Region, 2021–2030 (USD Million)
Table 39 Global Point-of-Care Diagnostics Market for Other Respiratory Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 40 Global PoC Diagnostics Market for Healthcare-associated Infection (HAI) Testing,by Country/Region, 2021–2030 (USD Million)
Table 41 Global Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Type, 2021–2030 (USD Million)
Table 42 Global Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 43 Global Point-of-Care Diagnostics Market for Salmonellosis, by Country/Region, 2021–2030 (USD Million)
Table 44 Global Point-of-Care Diagnostics Market for E. Coli Infections, by Country/Region, 2021–2030 (USD Million)
Table 45 Global Point-of-Care Diagnostics Market for Other GI Infections, by Country/Region, 2021–2030 (USD Million)
Table 46 Global Point-of-Care Diagnostics Market for Other Infectious Diseases Testing, by Country/Region, 2021–2030 (USD Million)
Table 47 Recently Launched and Approved Rapid Diagnostic Tests for COVID-19 Detection
Table 48 FDA-Authorized At-Home OTC COVID-19 Diagnostic Tests
Table 49 Global Point-of-Care Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 50 Key Companies Offering Tumor/Cancer Marker Testing Products
Table 51 Global Point-of-Care Diagnostics Market for Tumor/Cancer Markers Testing, by Country/Region, 2021–2030 (USD Million)
Table 52 Global Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Type, 2021–2030 (USD Million)
Table 53 Global Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Country/Region, 2021–2030 (USD Million)
Table 54 Key Companies Offering Point-of-Care Diagnostic Kits for Pregnancy Testing
Table 55 Global Point-of-Care Diagnostics Market for Pregnancy Testing, by Country/Region, 2021–2030 (USD Million)
Table 56 Key Companies Offering Point-of-Care Diagnostic Kits for Fertility Testing
Table 57 Global Point-of-Care Diagnostics Market for Fertility Testing, by Country/Region, 2021–2030 (USD Million)
Table 58 Key Companies Offering Point-of-Care Diagnostic Kits for Cardiac Metabolism Testing
Table 59 Global PoC Diagnostics Market for Cardiac Marker/Cardiac Metabolism Testing, by Country/Region, 2021–2030 (USD Million)
Table 60 Global Point-of-Care Diagnostics Market for Cholesterol/Lipid Profile Testing, by Country/Region, 2021–2030 (USD Million)
Table 61 Global Point-of-Care Diagnostics Market for Coagulation Testing, by Type, 2021–2030 (USD Million)
Table 62 Global Point-of-Care Diagnostics Market for Coagulation Testing, by Country/Region, 2021–2030 (USD Million)
Table 63 Global Point-of-Care Diagnostics Market for Prothrombin Time (PT/INR) Testing, by Country/Region, 2021–2030 (USD Million)
Table 64 Global PoC Market for Activated Clotting Time (ACT/APTT) Testing, by Country/Region, 2021–2030 (USD Million)
Table 65 Global Point-of-Care Diagnostics Market for Other Coagulation Testing, by Country/Region, 2021–2030 (USD Million)
Table 66 Global Point-of-Care Diagnostics Market for Hematology, by Country/Region, 2021–2030 (USD Million)
Table 67 Global Point-of-Care Diagnostics Market for Drugs of Abuse Testing, by Country/Region, 2021–2030 (USD Million)
Table 68 Global Point-of-Care Diagnostics Market for Urinalysis, by Country/Region, 2021–2030 (USD Million)
Table 69 Incidence of Tropical Diseases (2019)
Table 70 Global Point-of-Care Diagnostics Market for Other PoC Testing, by Country/Region, 2021–2030 (USD Million)
Table 71 Global Point-of-Care Diagnostics Market, by Sample Type, 2021–2030
Table 72 Global Point-of-Care Diagnostics Market for Blood Sample, by Country/Region, 2021–2030 (USD Million)
Table 73 Global Point-of-Care Diagnostics Market for Nasopharyngeal Swab, by Country/Region, 2021–2030 (USD Million)
Table 74 Reason for Conducting a Urine Test
Table 75 Global Point-of-Care Diagnostics Market for Urine Sample, by Country/Region, 2021–2030 (USD Million)
Table 76 PoC Devices for Salivary Biomarkers
Table 77 Global Point-of-Care Diagnostics Market for Saliva Sample, by Country/Region, 2021–2030 (USD Million)
Table 78 Sample Type for Various Test
Table 79 Global Point-of-Care Diagnostics Market for Other Sample Types, by Country/Region, 2021–2030 (USD Million)
Table 80 Global Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 81 Global Point-of-Care Diagnostics Market for Hospitals, by Country/Region, 2021–2030 (USD Million)
Table 82 Global Point-of-Care Diagnostics Market for Home Care/Self-testing, by Country/Region, 2021–2030 (USD Million)
Table 83 Global PoC Market for Physician Offices & Ambulatory Care Settings, by Country/Region, 2021–2030 (USD Million)
Table 84 Global Point-of-Care Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 85 Global Point-of-Care Diagnostics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 86 Point-of-Care Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 87 North America: Point-of-Care Diagnostics Market, by Country, 2021–2030
Table 88 North America: Point-of-Care Diagnostics Market, by Offering, 2021–2030
Table 89 North America: Point-of-Care Diagnostics Market, by Platform, 2021–2030
Table 90 North America: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 91 North America: Infectious Diseases Testing Market, by Type, 2021–2030
Table 92 North America: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 93 North America: Gastrointestinal Infections Market, by Type, 2021–2030
Table 94 North America: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 95 North America: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 96 North America: Pregnancy and Fertility Testing Market, by Type, 2021–2030
Table 97 North America: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 98 North America: Point-of-Care Diagnostics Market, by End User, 2021–2030
Table 99 Rapid Diagnostic Kits Launched for Coronavirus Testing
Table 100 U.S.: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 101 U.S.: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 102 U.S.: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 103 U.S.: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 104 U.S.: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 105 U.S.: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 106 U.S.: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 107 U.S.: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 108 U.S.: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 109 U.S.: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 110 U.S.: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 111 Canada: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 112 Canada: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 113 Canada: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 114 Canada: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 115 Canada: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 116 Canada: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 117 Canada: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 118 Canada: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 119 Canada: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 120 Canada: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 121 Canada: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 122 Europe: Point-of-Care Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 123 Europe: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 124 Europe: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 125 Europe: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 126 Europe: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 127 Europe: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 128 Europe: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 129 Europe: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 130 Europe: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 131 Europe: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 132 Europe: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030
Table 133 Europe: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 134 Recent Initiatives by the German Government to Tackle the COVID-19 Pandemic
Table 135 Germany: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 136 Germany: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 137 Germany: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 138 Germany: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 139 Germany: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 140 Germany: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 141 Germany: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 142 Germany: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 143 Germany: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 144 Germany: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 145 Germany: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 146 France: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 147 France: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 148 France: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 149 France: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 150 France: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 151 France: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 152 France: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 153 France: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 154 France: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 155 France: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 156 France: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 157 Recent Initiatives by the U.K. Government to Combat the COVID-19 Pandemic
Table 158 U.K.: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 159 U.K.: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 160 U.K.: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 161 U.K.: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 162 U.K.: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 163 U.K.: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 164 U.K.: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 165 U.K.: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 166 U.K.: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 167 U.K.: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 168 U.K.: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 169 Initiatives Undertaken by the Government of Italy to Tackle the COVID-19 Pandemic
Table 170 Italy: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 171 Italy: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 172 Italy: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 173 Italy: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 174 Italy: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 175 Italy: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 176 Italy: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 177 Italy: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 178 Italy: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 179 Italy: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 180 Italy: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 181 Spain: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 182 Spain: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 183 Spain: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 184 Spain: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 185 Spain: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 186 Spain: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 187 Spain: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 188 Spain: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 189 Spain: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 190 Spain: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 191 Spain: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 192 COVID-19 Cases in European Countries
Table 193 Rest of Europe: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 194 Rest of Europe: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 195 Rest of Europe: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 196 Rest of Europe: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 197 Rest of Europe: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 198 Rest of Europe: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 199 Rest of Europe: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 200 Rest of Europe: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 201 Rest of Europe: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 202 Rest of Europe: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 203 Rest of Europe: Point-of-Care Diagnostics Market, by End User, 2021–2030
Table 204 Asia-Pacific: Point-of-Care Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 205 Asia-Pacific: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 206 Asia-Pacific: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 207 Asia-Pacific: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 208 Asia-Pacific: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 209 Asia-Pacific: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 210 Asia-Pacific: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 211 Asia-Pacific: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 212 Asia-Pacific: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 213 Asia-Pacific: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 214 Asia-Pacific: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 215 Asia-Pacific: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 216 China: Mass Testing Drives to Control the Spread of COVID-19 Infections
Table 217 China: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 218 China: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 219 China: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 220 China: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 221 China: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 222 China: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 223 China: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 224 China: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 225 China: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 226 China: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 227 China: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 228 Japan: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 229 Japan: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 230 Japan: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 231 Japan: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 232 Japan: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 233 Japan: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 234 Japan: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 235 Japan: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 236 Japan: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 237 Japan: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 238 Japan: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 239 Recent Initiatives Launched by the Government of India to Combat The COVID-19 Pandemic
Table 240 India: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 241 India: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 242 India: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 243 India: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 244 India: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 245 India: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 246 India: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 247 India: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 248 India: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 249 India: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030(USD Million)
Table 250 India: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 251 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 252 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 253 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 254 Rest of Asia-Pacific: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 255 Rest of Asia-Pacific: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 256 Rest of Asia-Pacific: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 257 Rest of Asia-Pacific: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 258 Rest of Asia-Pacific: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 259 Rest of Asia-Pacific: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 260 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 261 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 262 Latin America: Point-of-Care Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 263 Latin America: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 264 Latin America: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 265 Latin America: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 266 Latin America: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 267 Latin America: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 268 Latin America: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 269 Latin America: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 270 Latin America: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 271 Latin America: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 272 Latin America: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 273 Latin America: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 274 Brazil: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 275 Brazil: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 276 Brazil: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 277 Brazil: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 278 Brazil: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 279 Brazil: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 280 Brazil: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 281 Brazil: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 282 Brazil: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 283 Brazil: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 284 Brazil: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 285 Mexico: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 286 Mexico: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 287 Mexico: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 288 Mexico: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 289 Mexico: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 290 Mexico: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 291 Mexico: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 292 Mexico: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 293 Mexico: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 294 Mexico: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 295 Mexico: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 296 Estimated Cancer Incidence
Table 297 People (20-79 Y) with Diabetes (In Thousands)
Table 298 Rest of Latin America: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 299 Rest of Latin America: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 300 Rest of Latin America: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 301 Rest of Latin America: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 302 Rest of Latin America: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 303 Rest of Latin America: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 304 Rest of Latin America: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 305 Rest of Latin America: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 306 Rest of Latin America: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 307 Rest of Latin America: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 308 Rest of Latin America: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 309 Middle East & Africa: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 310 Middle East & Africa: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 311 Middle East & Africa: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 312 Middle East & Africa: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 313 Middle East & Africa: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 314 Middle East & Africa: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 315 Middle East & Africa: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 316 Middle East & Africa: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 317 Middle East & Africa: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 318 Middle East & Africa: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 319 Middle East & Africa: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 320 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation and Growth Forecast Approach
Figure 7 Global Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030
Figure 8 Global Point-of-Care Diagnostics Market Size, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 9 Global Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030
Figure 11 Global Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030
Figure 12 Global Point-of-Care Diagnostics Market, by Geography
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Percentage Share of the Population Aged 65 Years and Above
Figure 15 Population Aged 65 years or Over, by Region, 2020 VS. 2030 (In Million)
Figure 16 EU Regulatory Pathway - IVDR 2017/746
Figure 17 China: Medical Device Classification and Pre-Market Requirements for PoC Diagnostic Devices
Figure 18 Global Point-of-Care Diagnostics Market, by Offering, 2023 VS. 2030
Figure 19 Global Point-of-Care Diagnostics Market, by Platform, 2023 VS. 2030
Figure 20 Global Point-of-Care Diagnostics Market, by Application, 2023 VS. 2030
Figure 21 Prevalence of Diabetes Across the World: 2015–2045 (In Million)
Figure 22 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Million)
Figure 23 Global Point-of-Care Diagnostics Market, by Sample Type, 2023 VS. 2030
Figure 24 Benefits of Saliva Sampling
Figure 25 Global Point-of-Care Diagnostics Market, by End User, 2023 VS. 2030
Figure 26 U.S.: Home Healthcare Spending, 2015–2026 (USD Million)
Figure 27 Point-of-Care Diagnostics Market, by Region, 2023 VS. 2030 (USD Million)
Figure 28 North America: Point-of-Care Diagnostics Market Snapshot
Figure 29 U.S.: Number of HIV-positive Patients, 2017–2020
Figure 30 Canada: Number of People Aged 65 Years and Above, 2018–2022 (In Thousand)
Figure 31 Canada: Number of Inpatient Admissions in Acute-Care Hospitals, 2016–2020 (per 100,000 Population)
Figure 32 Europe: Point-of-Care Diagnostics Market Snapshot
Figure 33 France: Percentage of Population Aged 65 Years and Above, 2016–2020
Figure 34 U.K: Estimated Number of Cancer Cases, 2020–2030
Figure 35 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Diseases Cases - DALYs (Disability-Adjusted Life Years), 2017–2020 (in Thousand)
Figure 36 U.K.: Number of People Diagnosed with Sexually Transmitted Infections
Figure 37 Italy: Prevalence of Healthcare-Associated Infections in Acute-Care Wards, 2016–2019
Figure 38 Italy: Ovarian Cancer Cases: 2018–2030
Figure 39 Number of HIV Tests Performed in Catalonia (Spain), 2014–2020
Figure 40 Health Expenditure (2015–2020)
Figure 41 Asia-Pacific: Point-of-Care Diagnostics Market Snapshot
Figure 42 China: Independent Medical Laboratories Market, 2015–2019 (USD Million)
Figure 43 Japan: Percentage Growth in the Aging Population (2015–2021)
Figure 44 Latin America: Point-of-Care Diagnostics Market Snapshot
Figure 45 Brazil: People Living with HIV
Figure 46 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 47 Competitive Dashboard: Point-of-Care Diagnostics Market
Figure 48 Market Share Analysis: Point-of-Care Diagnostics Market (2022)
Figure 49 Financial Overview: Abbott laboratories (2022)
Figure 50 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 51 Siemens Healthineers AG: Financial Overview (2022)
Figure 52 Danaher Corporation: Financial Overview (2022)
Figure 53 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 54 Becton, Dickinson and Company: Financial Overview (2022)
Figure 55 bioMérieux S.A.: Financial Overview (2022)
Figure 56 QuidelOrtho Corporation: Financial Overview (2022)
Figure 57 EKF Diagnostics Holdings plc: Financial Overview (2022)
Figure 58 Sekisui Chemical Co., Ltd.: Financial Overview (2021)
Figure 59 Trinity Biotech plc: Financial Overview (2021)
Figure 60 Chembio Diagnostics: Financial Overview (2021)
Figure 61 Werfen: Financial Overview (2021)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Burn Care Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Nov-2024
Europe Point-of-Care Diagnostics Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
U.S. Point-of-Care Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Hair Care Market - Global Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jun-2024
